Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Kadmon Pharmaceuticals, Nano Terra ink licensing agreement
June 2011
SHARING OPTIONS:

NEW YORK—Kadmon Pharmaceuticals LLC and Nano Terra Inc. have entered into a licensing agreement under which Kadmon has acquired a perpetual, worldwide exclusive license to three of Nano Terra's novel, clinical-stage product candidates in addition to rights to Pharmacomer Technology, Nano Terra's drug discovery platform. The platform and candidates will be transferred to a newly formed joint venture, NT Life Sciences, which is co-owned by Kadmon and Nano Terra. NT Life will serve as the licensor and recipient of any licensing or royalty fees that are subject to the agreement. Additional details were not disclosed. The candidates, which are in early- to mid-stage clinical development, target several pathways of disease by inhibiting the activity of specific enzymes. Dr. Samuel D. Waksal, chairman and CEO of Kadmon, says the agreement provides Kadmon with "remarkably well-developed clinical compounds targeting important pathways of disease as well as a powerful discovery engine."


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.